Papillary Renal Cell Carcinoma Recruiting Phase 2 Trials for Ipilimumab (DB06186)

IndicationStatusPhase
DBCOND0030667 (Papillary Renal Cell Carcinoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03866382Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsTreatment